Influenza and Respiratory Syncytial Virus (RSV) are seasonal respiratory viruses of significant public health importance. Each year an estimated 3 to 5 million cases of severe influenza illness occur globally, and between 250,000 and 500,000 people will die as a result of their infection. The young, the elderly, pregnant women and people with underlying medical conditions are at particular risk of severe infection.
RSV is the most common viral respiratory infection in children, with almost all children becoming infected by the age of two years. Infection typically causes mild symptoms similar to the common cold, but in some instances infection can be severe, especially in very young infants, premature infants or those with particular heart or lung conditions. There is no immunity to RSV and infections occur throughout life; RSV is increasingly recognised as a cause of excess winter mortality in the elderly.
This study seeks to describe the relationship between age and the risk of hospital admission for influenza and RSV, and on the relationship between age and severity. No formal testing of these relationships will be undertaken
This study seeks to generate counts, by age and length of admission, of patients admitted to hospital with influenza or RSV in England between 2010 and 2016. Counts will be split further by the primary nature of the hospital admissions (e.g. flu or RSV respectively was recorded as the primary reason for hospital admission), the incident nature of the hospital admissions (e.g. if a patients had previous admissions in the 90 days prior to each admission) and whether patients were admitted to intensive care units or were mechanically ventilated. The data will also be stratified by the need for critical care and mechanical ventilation.
This study seeks to describe the relationship between age and the risk of hospital admission for influenza and RSV, and on the relationship between age and severity. No formal testing of these relationships will be undertaken
Iain Gillespie - Chief Investigator - GlaxoSmithKline Research & Development Limited (UK)
Iain Gillespie - Corresponding Applicant - GlaxoSmithKline Research & Development Limited (UK)
Joe Maskell - Collaborator - Amgen Ltd
John Logie - Collaborator - GlaxoSmithKline Research & Development Limited (UK)
HES Admitted Patient Care;HES Admitted Patient Care